FDA approved ingenol mebutate (Picato, LEO Pharma) gel (0.015%, 0.05%) for the topical treatment of actinic keratosis (AK). It is the first topical AK therapy that can be used for as few as 2 or 3 consecutive days.
FDA approved ingenol mebutate (Picato, LEO Pharma) gel (0.015%, 0.05%) for the topical treatment of actinic keratosis (AK). It is the first topical AK therapy that can be used for as few as 2 or 3 consecutive days.
AK is a precancerous condition caused by cumulative sun exposure that has the potential to progress to squamous cell carcinoma (SCC), the second most common type of skin cancer. Picato 0.015% gel is used once daily on the face and scalp for 3 consecutive days; Picato 0.05% gel is used once daily on the trunk and extremities for 2 consecutive days.
“The approval of Picato gel is very exciting as it will give physicians and health plans an effective 2- or 3-day topical solution for actinic keratosis, which can lead to squamous cell carcinoma,” John Koconis, president and CEO of LEO Pharma, told Formulary.
According to the American Academy of Dermatology (AAD), 1 in 5 Americans will develop skin cancer in the course of their lifetime. Studies show that about 65% of SCCs begin as untreated AK, and guidelines from the AAD estimate that 60% of predisposed persons older than age 40 years have at least 1 actinic keratosis.
“Since there is no way to predict which actinic keratosis will advance to skin cancer, early detection and treatment of lesions are critical,” said ingenol mebutate study investigator Mark Lebwohl, MD, department of dermatology, Mount Sinai Medical Center, New York. “What makes this new solution particularly exciting is the 2- or 3-day course of treatment.”
In 4 phase 3 clinical studies of more than 1,000 patients with AK, a significantly higher proportion of those treated with Picato gel (n=503) saw complete clearance of AKs in the field of treatment as compared to placebo (n=502). The most common adverse events were local skin reactions, including erythema, flaking/scaling, crusting, and swelling.
Picato gel is for topical use only; not for oral, ophthalmic, or intravaginal use. Eye disorders, including severe eye pain, eyelid edema, eyelid ptosis, and periorbital edema, can occur after exposure. Patients should wash hands well after applying Picato gel, and avoid transfer of the drug to the periocular area during and after application. Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/pustulation, and erosion/ulceration, can occur after application. Administration of Picato gel is not recommended until the skin is healed from any previous drug or surgical treatment.
The most common adverse reactions observed in clinical trials (≥2%) are local skin reactions, application-site pain, application-site pruritus, application-site irritation, application-site infection, periorbital edema, nasopharyngitis, and headache.
There are no adequate and well-controlled studies of Picato gel in pregnant women. Picato gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The safety and effectiveness of Picato gel for AK in patients less than 18 years of age have not been established.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.